• Hai-Yan Dai, Jia-Ying Wang, Yan-Qing Li, Hui-Jie Diao, and Li Zhang.
• Second Ward of Ophthalmology Department.
• Medicine (Baltimore). 2018 Dec 1; 97 (51): e13833.

BackgroundLatanoprost is quiet new formulation that is approved for the treatment of primary open angle glaucoma (POAG). However, no updated systematic review has addressed its efficacy for POAG. This systematic review of randomized controlled trials (RCTs) aims to assess its efficacy and safety for the treatment of patients with POAG.MethodsThis study will search the databases of CENTRAL, EMBASE, MEDILINE, CINAHL, AMED and Chinese databases without language restrictions from their inception to the present. It will only include RCTs of latanoprost for POAG. The quality of the included RCTs will be evaluated by the tool of Cochrane risk of bias. The primary outcomes will be measured by the mean IOP reduction from baseline to the endpoint. The secondary outcomes will be assessed by the mean IOP, adjusted mean IOP reduction at each time point, quality of life, and adverse events. The RevMan V.5.3 software will be used to compute the data synthesis carefully if the meta-analysis is allowed. The summary results of the included RCTs will be conducted by using the models of random-effects or fixed-effects based.ResultsThe results of this study will be published at the peer-reviewed journals. It will provide evidence to determine the efficacy and safety of latanoprost for POAG.ConclusionThe results of this study will provide helpful evidence for both clinicians and patients, and for the health policy makers to refer for the policy or guideline making.Systematic Review RegistrationPROSPERO CRD42018115416.

12 keywords...

hide…